{"disease":{"id":"alzheimers-disease","name":"Alzheimer\\","therapeutic_area":"Neurology","data":{"aiSummary":"The treatment landscape for Alzheimer\\","drug_count":5,"description":"Alzheimer\\","subtype_count":8},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.907Z","updated_at":"2026-03-25T12:16:34.907Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07177352","title":"Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":13000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03131453","title":"A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":1145,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07058129","title":"Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":814,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07169578","title":"A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07170150","title":"A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02565511","title":"A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":480,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02409082","title":"Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT07073066","title":"Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":376,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05552157","title":"A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04498650","title":"A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"Vivoryon Therapeutics N.V.","has_results":false},{"nct_id":"NCT04639050","title":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":241,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06996730","title":"A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Banner Health","has_results":false},{"nct_id":"NCT07399171","title":"Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Halia Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06424236","title":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05015803","title":"Enhanced CBTi for Older Adult Sleep and Cognition","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Penn State University","has_results":false},{"nct_id":"NCT07496021","title":"Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"CKD Bio Corporation","has_results":false},{"nct_id":"NCT07212062","title":"The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Neurology Office of South Florida","has_results":false},{"nct_id":"NCT04023994","title":"A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05097131","title":"An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US","phase":"","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07233512","title":"EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":26,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05256134","title":"A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05891496","title":"A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT06831812","title":"Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Nuravax, Inc.","has_results":true},{"nct_id":"NCT07216716","title":"Evaluating the Effectiveness of the Health App Recommendation Tool","phase":"NA","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT06484244","title":"Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Emory University","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}